Ulta Partnership Adds Optionality, But Transformation Risks Remain

What happened

A Seeking Alpha article bullish on Bath & Body Works cites a Q1 beat, $600M FCF guidance, and the new Ulta Beauty partnership as reasons for a Strong Buy rating, arguing the stock is deeply discounted relative to robust fundamentals. However, the DeepValue master report paints a more cautious picture: the company is in the midst of a two-year “Consumer First Formula” transformation, comparable sales are still declining, and the CEO has warned that growth may not return until 2027. While the Ulta partnership and planned Amazon launch provide new distribution levers, the report highlights that BBWI is losing share to fragrance peers, promotional intensity remains high, and the cost savings from the transformation are largely being reinvested, not dropped to the bottom line. The DeepValue report rates the stock a “WAIT” with a conviction of 3.5/5, seeing limited upside in the next 6–18 months until there is clearer evidence of comp stabilization and margin recovery. In essence, the bullish article focuses on valuation and potential catalysts, but the deeper analysis suggests execution risk and secular headwinds are not yet priced in, making a compelling entry more likely below $18.

Implication

The Ulta and Amazon partnerships are real catalysts that could expand BBWI's reach to younger consumers, but they will take time to materialize and may initially pressure margins. The DeepValue report's base case implies a $24 fair value, but only if comps stabilize by 2027. Investors should monitor holiday 2026 results and evidence that the cost savings program is translating into sustainable margin improvement. Until then, the stock's low valuation is justified by the risk of prolonged underperformance.

Thesis delta

The new article introduces concrete near-term catalysts (Ulta, Amazon, Q1 beat) that were less emphasized before, but the DeepValue report's fundamental concerns—share loss, promo addiction, and a recovery not expected until 2027—remain unchanged. The thesis shifts from purely valuation-driven to one where catalysts exist but are not yet proven; the risk/reward remains unfavorable without visible traction on comps and margins.